429 related articles for article (PubMed ID: 33216223)
1. COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience.
Preziosa P; Rocca MA; Nozzolillo A; Moiola L; Filippi M
J Neurol; 2021 Aug; 268(8):2697-2699. PubMed ID: 33216223
[No Abstract] [Full Text] [Related]
2. MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
Seferoğlu M; Ethemoğlu Ö; Turan ÖF; Siva A
Neurol Sci; 2021 Sep; 42(9):3533-3535. PubMed ID: 34165650
[TBL] [Abstract][Full Text] [Related]
3. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 in Cladribine-treated patient with multiple sclerosis.
Haham N; Vaknin-Dembinsky A
J Neuroimmunol; 2021 Oct; 359():577690. PubMed ID: 34390951
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
6. Oral cladribine and fingolimod for relapsing multiple sclerosis.
Li H; Zhang X
N Engl J Med; 2010 May; 362(18):1738-9; author reply 1739-40. PubMed ID: 20449878
[No Abstract] [Full Text] [Related]
7. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
8. Cladribine in multiple sclerosis: pitfalls in a new treatment landscape.
Paul F
Expert Opin Pharmacother; 2013 Jan; 14(1):1-3. PubMed ID: 23256603
[No Abstract] [Full Text] [Related]
9. Cladribine (Mavenclad) for multiple sclerosis.
Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
[No Abstract] [Full Text] [Related]
10. An update on cladribine for relapsing-remitting multiple sclerosis.
Holmøy T; Torkildsen Ø; Myhr KM
Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
[TBL] [Abstract][Full Text] [Related]
11. Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
Schmierer K; Wiendl H; Oreja-Guevara C; Centonze D; Chudecka A; Roy S; Boschert U
Mult Scler; 2022 Nov; 28(13):2151-2153. PubMed ID: 35672923
[No Abstract] [Full Text] [Related]
12. [Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis].
Avxentyev NA; Davydovskaya MV; Makarova YV; Frolov MY; Klabukova DL
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):30-36. PubMed ID: 34481433
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
14. Cladribine for multiple sclerosis.
Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
[TBL] [Abstract][Full Text] [Related]
15. Oral cladribine and fingolimod for relapsing multiple sclerosis.
Mann H
N Engl J Med; 2010 May; 362(18):1738; author reply 1739-40. PubMed ID: 20445188
[No Abstract] [Full Text] [Related]
16. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.
Sipe JC
Expert Rev Neurother; 2010 Mar; 10(3):365-75. PubMed ID: 20187859
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
Capone F; Ferraro E; Motolese F; Di Lazzaro V
J Neurol; 2021 Sep; 268(9):3132-3134. PubMed ID: 33611610
[No Abstract] [Full Text] [Related]
18. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
19. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis.
Tafazzoli A; Chavan A; Harty G; Moller J; Wong SL
Adv Ther; 2020 Sep; 37(9):3791-3806. PubMed ID: 32647909
[TBL] [Abstract][Full Text] [Related]
20. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
[Next] [New Search]